Citations

Clear

7 citation(s) found for "Hong, Tao".

Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD
Heerspink, Hiddo J.L. , Inker, Lesley A. , Collier, Willem , Haaland, Benjamin , Luo, Jiyu , Appel, Gerald B., Estacio, Raymond O. , Fervenza, Fernando C. , Floege, Jürgen , Imai, Enyu , Jafar, Tazeen H. , Lewis, Julia B. , Li, Philip Kam‐Tao , Maes, Bart , Praga, Manuel , CT, on behalf of CKD-EPI, Floege, Jürgen , Luo, Jiyu , Fervenza, Fernando, Li, Philip Kam-Tao , Torres, Vicente E , Greene, Tom , Fervenza, Fernando C , Tighiouart, Hocine , Chan, Tak Mao , Locatelli, Francesco , Perna, Annalisa , Perrone, Ronald D. , Schena, Francesco Paolo , Wanner, Christoph , Xie, Di, Greene, Tom , CT, on behalf of CKD-EPI

Mayo Clinic

Journal of the American Society of Nephrology | March 15, 2023 | Volume: 34 | Issue: 6 | Pages: 955-968

10.1681/asn.0000000000000117 | PMID 36918388 Get It

Significance Statement Changes in albuminuria and GFR slope are individually used as surrogate end points in clinical trials of CKD progression, and studies have demonstrated that each is associated with treatment effects on clinical end points. In this study, the authors sought to develop a conceptual framework that combines both surrogate end points to better predict treatment effects on clinical end points in Phase 2 trials. The results demonstrate that information from the combined treatment effects on albuminuria and GFR slope improves the prediction of treatment effects on the clinical end point for Phase 2 trials with sample sizes between 100 and 200 patients and duration of follow-up ranging from 1 to 2 years. These findings may help inform design of clinical trials for interventions aimed at slowing CKD progression. Background Changes in log urinary albumin-to-creatinine ratio (UACR) and GFR slope are individually used as surrogate end points in clinical trials of CKD progression. Whether combining these surrogate end points might strengthen inferences about clinical benefit is unknown. Methods Using Bayesian meta-regressions across 41 randomized trials of CKD progression, we characterized the combined relationship between the treatment effects on the clinical end point (sustained doubling of serum creatinine, GFR <15 ml/min per 1.73 m 2 , or kidney failure) and treatment effects on UACR change and chronic GFR slope after 3 months. We applied the results to the design of Phase 2 trials on the basis of UACR change and chronic GFR slope in combination. Results Treatment effects on the clinical end point were strongly associated with the combination of treatment effects on UACR change and chronic slope. The posterior median meta-regression coefficients for treatment effects were −0.41 (95% Bayesian Credible Interval, −0.64 to −0.17) per 1 ml/min per 1.73 m 2 per year for the treatment effect on GFR slope and −0.06 (95% Bayesian Credible Interval, −0.90 to 0.77) for the treatment effect on UACR change. The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up. Conclusions In Phase 2 trials of CKD with sample sizes of 100–200 patients per arm and follow-up between 1 and 2 years, combining information from treatment effects on UACR change and GFR slope improved the prediction of treatment effects on clinical end points.
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Neuen, Brendon L. , Vonesh, Edward F. , Chaudhari, Juhi, Miao, Shiyuan , Fervenza, Fernando C. , Floege, Jürgen , Goicoechea, Marián , Imai, Enyu , Jafar, Tazeen H. , Lewis, Julia B. , Li, Philip Kam‐Tao , Locatelli, Francesco , Maes, Bart , Praga, Manuel , Woodward, Mark , Xie, Di , Inker, Lesley A. , Floege, Jürgen , Herrington, William G , Li, Philip Kam-Tao , Torres, Vicente E , Wanner, Christoph , Woodward, Mark , Greene, Tom , Fervenza, Fernando C , Tighiouart, Hocine , Heerspink, Hiddo J.L. , Chan, Tak Mao , Perrone, Ronald D. , Perna, Annalisa , Schena, Francesco Paolo , Wetzels, Jack F.M. , Greene, Tom

Mayo Clinic

Journal of the American Society of Nephrology | December 3, 2021 | Volume: 33 | Issue: 2 | Pages: 291-303

10.1681/asn.2021070948 | PMID 34862238 Get It

Background Acute changes in GFR can occur after initiation of interventions targeting progression of CKD. These acute changes complicate the interpretation of long-term treatment effects. Methods To assess the magnitude and consistency of acute effects in randomized clinical trials and explore factors that might affect them, we performed a meta-analysis of 53 randomized clinical trials for CKD progression, enrolling 56,413 participants with at least one estimated GFR measurement by 6 months after randomization. We defined acute treatment effects as the mean difference in GFR slope from baseline to 3 months between randomized groups. We performed univariable and multivariable metaregression to assess the effect of intervention type, disease state, baseline GFR, and albuminuria on the magnitude of acute effects. Results The mean acute effect across all studies was −0.21 ml/min per 1.73 m 2 (95% confidence interval, −0.63 to 0.22) over 3 months, with substantial heterogeneity across interventions (95% coverage interval across studies, −2.50 to +2.08 ml/min per 1.73 m 2 ). We observed negative average acute effects in renin angiotensin system blockade, BP lowering, and sodium-glucose cotransporter 2 inhibitor trials, and positive acute effects in trials of immunosuppressive agents. Larger negative acute effects were observed in trials with a higher mean baseline GFR. Conclusion The magnitude and consistency of acute GFR effects vary across different interventions, and are larger at higher baseline GFR. Understanding the nature and magnitude of acute effects can help inform the optimal design of randomized clinical trials evaluating disease progression in CKD.
Flow Diversion for Middle Cerebral Artery Aneurysms: An International Cohort Study
Diestro, Jose Danilo Bengzon , Adeeb, Nimer , Dibas, Mahmoud , Boisseau, William , Harker, Pablo , Brinjikji, Waleed , Xiang, Sishi, Joyce, Evan, Shapiro, Maksim , Raz, Eytan , Pickett, Gwynedd E. , Alotaibi, Naif M. , Regenhardt, Robert W. , Spears, Julian , Burkhardt, Jan‐Karl , Hafeez, Muhammad Ubaid , Kan, Peter , Nossek, Erez , Zhang, Hongqi , Rinaldo, Lorenzo , Stapleton, Christopher J. , Rabinov, James D. , Patel, Aman B. , Marotta, Thomas R. , Dmytriw, Adam A. , Burkhardt, Jan-Karl , Kan, Peter , Rinaldo, Lorenzo , Lanzino, Giuseppe , Dmytriw, Adam A , Dibas, Mahmoud , Diestro, Jose Danilo B , Harker, Pablo , Regenhardt, Robert W , Hafeez, Muhammad U , Burkhardt, Jan‐Karl , Parra-Fariñas, Carmen , Bernstock, Joshua D. , Griessenauer, Christoph J. , Grandhi, Ramesh , Taussky, Philipp , Hong, Tao , Lanzino, Giuseppe , Roy, Daniel C.

Mayo Clinic

Neurosurgery | September 8, 2021 | Volume: 89 | Issue: 6 | Pages: 1112-1121

10.1093/neuros/nyab365 | PMID 34624100 Get It

Abstract BACKGROUND Open surgery has traditionally been preferred for the management of bifurcation middle cerebral artery (MCA) aneurysms. Flow diverting stents present a novel endovascular strategy for aneurysm treatment. OBJECTIVE To add to the limited literature describing the outcomes and complications in the use of flow diverters for the treatment of these complex aneurysms. METHODS This is a multicenter retrospective review of MCA bifurcation aneurysms undergoing flow diversion. We assessed post-treatment radiological outcomes and both thromboembolic and hemorrhagic complications. RESULTS We reviewed the outcomes of 54 aneurysms treated with flow diversion. Four (7.4%) of the aneurysms had a history of rupture (3 remote and 1 acute). Fourteen (25.9%) of the aneurysms already underwent either open surgery or coiling prior to flow diversion. A total of 36 out of the 45 aneurysms (80%) with available follow-up data had adequate aneurysm occlusion with a median follow-up time of 12 mo. There were no hemorrhagic complications but 16.7% (9/54) had thromboembolic complications. CONCLUSION Flow diverting stents may be a viable option for the endovascular treatment of complex bifurcation MCA aneurysms. However, compared to published series on the open surgical treatment of this subset of aneurysms, flow diversion has inferior outcomes and are associated with a higher rate of complications.
Comparison of PED and FRED flow diverters for posterior circulation aneurysms: a propensity score matched cohort study
Enríquez-Marulanda, Alejandro , Xiang, Sissi, Zhang, Hongqi , Waqas, Muhammad , Tutino, Vincent M. , Siddiqui, Adnan H. , Ogilvy, Christopher S. , Ulfert, Christian , Möhlenbruch, Markus , Renieri, Leonardo , Limbucci, Nicola , Burkhardt, Jan‐Karl , Kan, Peter , Rinaldo, Lorenzo , Brinjikji, Waleed , Spears, Julian , Broussalis, Erasmia , Koçer, Naci , Sonnberger, Michael , Engelhorn, Tobias , Ghuman, Mandeep S. , Salehani, Arsalaan , Harrigan, Mark R. , Radovanovic, Ivan , Chen, Karen , Aziz‐Sultan, Mohammad Ali , Ghorbani, Mohammad , Schirmer, Clemens M. , Goren, Oded , Dalal, Shamsher , Koch, Matthew J. , Stapleton, Christopher J. , Patel, Aman B. , Finkenzeller, Thomas , Holtmannspötter, Markus, Buhk, Jan Hendrik, Foreman, Paul M. , Cress, Marshall C. , Hirschl, Robert , Reith, W. , Janssen, Hendrik , Marotta, Thomas R. , Dmytriw, Adam A. , Waqas, Muhammad , Siddiqui, Adnan H , Levy, Elad I , Thomas, Ajith J , Renieri, Leonardo , Parra-Fariñas, Carmen , Rinaldo, Lorenzo , Brinjikji, Waleed , Müller-Thies-Broussalis, Erasmia , Killer-Oberpfalzer, Monika , Koch, Matthew J , Simgen, Andreas , Janssen, Hendrik , Marotta, Thomas R , Dmytriw, Adam A , Tutino, Vincent M , Schirmer, Clemens M , Ulfert, Christian , Limbucci, Nicola , Ogilvy, Christopher S , Griessenauer, Christoph J. , Hong, Tao , Taussky, Philipp , Grandhi, Ramesh , Levy, Elad I. , Lanzino, Giuseppe , Işlak, Civan , Yang, Victor X. D. , Mendes Pereira, Vitor , Krings, Timo , Matouk, Charles

Mayo Clinic

Journal of NeuroInterventional Surgery | July 1, 2020 | Volume: 13 | Issue: 2 | Pages: 153-158

10.1136/neurintsurg-2020-016055 | PMID 32611622 Get It

Abstract Background Flow diversion is a common endovascular treatment for cerebral aneurysms, but studies comparing different types of flow diverters are scarce. Objective To perform a propensity score matched cohort study comparing the Pipeline Embolization Device (PED) and Flow Redirection Intraluminal Device (FRED) for posterior circulation aneurysms. Methods Consecutive aneurysms of the posterior circulation treated at 25 neurovascular centers with either PED or FRED were collected. Propensity score matching was used to control for age, duration of follow-up imaging, adjunctive coiling, and aneurysm location, size, and morphology; previously ruptured aneurysms were excluded. The two devices were compared for the following outcomes: procedural complications, aneurysm occlusion, and functional outcome. Results A total of 375 aneurysms of the posterior circulation were treated in 369 patients. The PED was used in 285 (77.2%) and FRED in 84 (22.8%) procedures. Aneurysms treated with the PED were more commonly fusiform and larger than those treated with FRED. To account for these important differences, propensity score matching was performed resulting in 33 PED and FRED unruptured aneurysm pairs. No differences were found in occlusion status and neurologic thromboembolic or hemorrhagic complications between the two devices. The proportion of patients with favorable functional outcome was higher with FRED (100% vs 87.9%, p=0.04). Conclusion Comparative analysis of PED and FRED for the treatment of unruptured posterior circulation aneurysms did not identify significant differences in aneurysm occlusion or neurologic complications. Variations in functional outcomes warrant additional investigations.
Experience With the Pipeline Embolization Device for Posterior Circulations Aneurysms: A Multicenter Cohort Study
Enríquez-Marulanda, Alejandro , Biswas, Arundhati , Xiang, Sissi, Rinaldo, Lorenzo , Brinjikji, Waleed , Burkhardt, Jan‐Karl , Kan, Peter , Ghuman, Mandeep S. , Chen, Karen , Aziz‐Sultan, Mohammad Ali , Ghorbani, Mohammad , Schirmer, Clemens M. , Goren, Oded , Dalal, Shamsher , Broussalis, Erasmia , Koch, Matthew J. , Stapleton, Christopher J. , Patel, Aman B. , Foreman, Paul M. , Cress, Marshall C. , Hirschl, Robert , Zhang, Hongqi , Dmytriw, Adam A. , Rinaldo, Lorenzo , Dmytriw, Adam A , Schirmer, Clemens M , Griessenauer, Christoph J. , Taussky, Philipp , Grandhi, Ramesh , Hong, Tao , Lanzino, Giuseppe , Yang, Victor X. D. , Killer-Oberpfalzer, Monika , Krings, Timo

Mayo Clinic

Neurosurgery | June 5, 2020 | Volume: 87 | Issue: 6 | Pages: 1252-1261

10.1093/neuros/nyaa277 | PMID 32629474 Get It

Abstract BACKGROUND The Pipeline Embolization Device (PED; Medtronic) has been used off-label for the treatment of challenging posterior circulation aneurysms. Data on this modality are primarily limited to small retrospective single-center series. OBJECTIVE To assess safety and efficacy of this treatment by establishing an international, multicenter collaboration. METHODS Consecutive posterior circulation aneurysms treated with the PED from 2012 to 2019 across 11 neurovascular centers were retrospectively reviewed. Baseline demographics, aneurysm and treatment characteristics, complications, occlusion status, and functional outcome were assessed. RESULTS There were 149 posterior circulation aneurysms treated with PED in 146 patients. A total of 24 (16.4%) patients presented with subarachnoid hemorrhage. Most aneurysms were dissecting/blister (36.2%) in morphology, followed by saccular (35.6%) and fusiform (28.2%). The most common locations were the vertebral (51.7%) and basilar arteries (22.8%). Complete or near-complete occlusion (>90%) was achieved in 90.9% of aneurysms at a median follow-up of 12 mo. Dissecting/blister aneurysms were most likely to occlude ( P = .06). Symptomatic neurologic complications occurred in 9.4% of aneurysms, associated with larger size, ruptured presentation, presentations with brain stem compression, cranial nerve palsy, or stroke. Favorable functional outcome (modified Rankin Score 0-2) was achieved in 86.2% of patients. There were 6 fatalities of which 4 occurred in aneurysmal subarachnoid hemorrhage patients. CONCLUSION This multicenter study shows that PED for the treatment of posterior circulation is preferentially used for the treatment of fusiform and dissecting/blister aneurysm morphologies. Despite the challenges presented by these less-common morphologies, flow diversion may be performed with a neurologic complication rate of about 10% and favorable long-term aneurysm occlusion rates.
A phase IB trial of 5-azacitidine (5AC) and suberoylanilide hydroxamic acid (SAHA) in patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC) and NK-T cell lymphoma.
Tan, Eng Huat, Soo, Ross A. , Lee, Soo Chin , Low, John Soon Wah, Lim, Pei Li, Loh, Thomas Kwok Seng, Ames, Matthew M. , Murray, Paul Gerard, Hsieh, Wen Son, Lim, Wan‐Teck , Chan, Anthony T.�C. , Hui, Edwin Pun , Reid, Joel M. , Murray, Paul Gerard , Tao, Qian , Goh, Boon Cher , Ambinder, Richard F.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: e17017-e17017

10.1200/jco.2013.31.15_suppl.e17017 Get It

e17017 Background: Epigenetic up-regulation of EBV and cellular genes via demethylation and histone deacetylase inhibition can induce EBV lytic replication enhancing immune mediated tumor killing and up-regulation of tumor suppressor genes resulting in tumor apoptosis. Methods: Patients (Pt) with relapsed or refractory NPC and NK-T cell lymphomas were enrolled to determine safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity using a dose escalation design. 5AC was administered on days 1 to 10 sub-cutaneously while SAHA was administered on days 1 to 14 orally. PK for SAHA, EBV viral load, characterization of circulating EBV, Immunohistochemistry (IHC) and EBV promoter methylation analysis in tumor tissue were performed. Results: 11 pt have been treated (M:F 8:3, median age 48, R: 35-71) at 3 dose levels – 5AC 50 mg/m2 and SAHA 200 mg b.i.d. (dose level 1), 5AC 37.5 mg/m2 and SAHA 200 mg q. am and 100 mg q. pm (dose level 2), and 5AC 25 mg/m2 and SAHA 100 mg b.i.d (dose level 3). Median number of previous treatment regimens was 3 (R:1-6). Dose limiting toxicities (DLT) were seen in 2/2 pts at dose level 1: grade 4 thrombocytopenia (1 pt), grade 3 nausea, vomiting and fatigue (2 pts), and grade 5 hepatic failure (1 pt). Two of six patients at dose level 2 experienced DLT: grade 3 fatigue (1 pt) and worsening of pre-existing Sweet’s Syndrome (1 pt). Common AEs (G1/2) included fatigue (73%), cough (64%), anorexia (55%), and injection site reaction (45%). One minor response was seen and 5 pt had prolonged stable disease (>16 weeks), including one patient for 88 weeks. Analysis of post-treatment tumor biopsies showed demethylation of EBV lytic cycle gene promoters after treatment. SAHA PK, IHC results for EBV gene expression in tumor tissue, EBV viral load and characterization of circulating EBV will be presented. Conclusions: 5AC/SAHA appears to be tolerable at dose level 3 with suggestion of clinical benefit. Analysis of post-treatment tumor and blood samples suggests that modulation of EBV gene expression may play a role in the mechanism underlying clinical benefit. Continued accrual at dose level 3 is ongoing. Clinical trial information: NCT00336063.